Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16121132 | 0.85 | CYP2D6 (0.41) | SLC6A2SLC6A4KCNH2SLC6A3CYP2D6 | |
| SCHEMBL14035305 | 0.84 | MEN1 (0.59) | SLC6A2SLC6A4KCNH2SLC6A3CYP2D6 | |
| SCHEMBL4095744 | 0.84 | MEN1 (0.59) | SLC6A2SLC6A4KCNH2SLC6A3CYP2D6 | |
| SCHEMBL14035482 | 0.84 | MEN1 (0.59) | SLC6A2SLC6A4KCNH2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL23211984 | 0.83 | MEN1 (0.58) | SLC6A2SLC6A4KCNH2SLC6A3CYP2D6 | |
| SCHEMBL13723347 | 0.79 | HRH3 (0.46) | SLC6A2SLC6A4KCNH2SLC6A3CYP2D6 | |
| SCHEMBL13723937 | 0.79 | HRH3 (0.46) | SLC6A2SLC6A4KCNH2SLC6A3CYP2D6 | |
| SCHEMBL336219 | 0.78 | CYP2D6 (0.67) | SLC6A2SLC6A4KCNH2SLC6A3CYP2D6 | |
| SCHEMBL23212066 | 0.78 | SLC6A2 (0.39) | SLC6A2SLC6A4KCNH2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL21381611 | 0.76 | SLC6A2 (0.38) | SLC6A2SLC6A4KCNH2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | SLC6A2 4783/4885SLC6A4 4841/4885KCNH2 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.